The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study
Subcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials. A total of 58 allergic rhinitis patients sensitised to house dust mites, with or witho...
Gespeichert in:
| Veröffentlicht in: | Journal of laryngology and otology 2019-03, Vol.133 (3), p.213-219 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 219 |
|---|---|
| container_issue | 3 |
| container_start_page | 213 |
| container_title | Journal of laryngology and otology |
| container_volume | 133 |
| creator | Tu, Y Zhang, H Zhao, L Jin, P Zi, X Li, T Shi, L Zhi, L |
| description | Subcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.
A total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.
After two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p < 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.
Two-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients. |
| doi_str_mv | 10.1017/S0022215119000094 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2179419356</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><cupid>10_1017_S0022215119000094</cupid><sourcerecordid>2209531343</sourcerecordid><originalsourceid>FETCH-LOGICAL-c373t-beaf4cd3f1609b60c28afe28c75d9ba724719c8f37903bac4ed0709ed5405b563</originalsourceid><addsrcrecordid>eNp1kUtv1DAUhS0EotPCD2CDLLFh0YAdO_GYHRrxkip1QVlHftxMXCVx8AOUX8LfxdMZQGrF3XhxvnPutQ5CLyh5QwkVb78SUtc1bSiVpIzkj9CGCr6tGt6Sx2hzkKuDfobOY7wtCBWkforOGGkFZ43YoF83A2AzqHkPEbsZW9f3EGBOOK7TkvyEo_GhaDYHN-9xzNrkpGbwufDTlGefBghqWQ_u3eBmiICHokKxxIQnlwCrcYSwdwYvKrkSHt9hhdNPX62gwiX2OkL4USQ_qxHHlO36DD3p1Rjh-em9QN8-frjZfa6urj992b2_qgwTLFUaVM-NZT1tidQtMfVW9VBvjWis1ErUXFBptj0TkjCtDAdLBJFgG04a3bTsAr0-5i7Bf88QUze5aGAcj1_saiokp5Ldoa_uobc-h3JxoWoiG0YZZ4WiR8oEH2OAvluCm1RYO0q6Q2vdg9aK5-UpOesJ7F_Hn5oKwE6hatLB2T382_3_2N8Mw6Qp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2209531343</pqid></control><display><type>article</type><title>The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study</title><source>Cambridge University Press Journals Complete</source><creator>Tu, Y ; Zhang, H ; Zhao, L ; Jin, P ; Zi, X ; Li, T ; Shi, L ; Zhi, L</creator><creatorcontrib>Tu, Y ; Zhang, H ; Zhao, L ; Jin, P ; Zi, X ; Li, T ; Shi, L ; Zhi, L</creatorcontrib><description>Subcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.
A total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.
After two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p < 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.
Two-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients.</description><identifier>ISSN: 0022-2151</identifier><identifier>EISSN: 1748-5460</identifier><identifier>DOI: 10.1017/S0022215119000094</identifier><identifier>PMID: 30674357</identifier><language>eng</language><publisher>Cambridge, UK: Cambridge University Press</publisher><subject>Allergic rhinitis ; Allergies ; Asthma ; Clinical trials ; Histamine ; Hospitals ; Immunotherapy ; Main Articles ; Nose ; Observational studies ; Otolaryngology ; Patients ; Quality of life ; Questionnaires ; Systematic review</subject><ispartof>Journal of laryngology and otology, 2019-03, Vol.133 (3), p.213-219</ispartof><rights>Copyright © JLO (1984) Limited, 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c373t-beaf4cd3f1609b60c28afe28c75d9ba724719c8f37903bac4ed0709ed5405b563</citedby><cites>FETCH-LOGICAL-c373t-beaf4cd3f1609b60c28afe28c75d9ba724719c8f37903bac4ed0709ed5405b563</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.cambridge.org/core/product/identifier/S0022215119000094/type/journal_article$$EHTML$$P50$$Gcambridge$$H</linktohtml><link.rule.ids>164,314,776,780,27903,27904,55606</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30674357$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tu, Y</creatorcontrib><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Zhao, L</creatorcontrib><creatorcontrib>Jin, P</creatorcontrib><creatorcontrib>Zi, X</creatorcontrib><creatorcontrib>Li, T</creatorcontrib><creatorcontrib>Shi, L</creatorcontrib><creatorcontrib>Zhi, L</creatorcontrib><title>The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study</title><title>Journal of laryngology and otology</title><addtitle>J. Laryngol. Otol</addtitle><description>Subcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.
A total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.
After two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p < 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.
Two-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients.</description><subject>Allergic rhinitis</subject><subject>Allergies</subject><subject>Asthma</subject><subject>Clinical trials</subject><subject>Histamine</subject><subject>Hospitals</subject><subject>Immunotherapy</subject><subject>Main Articles</subject><subject>Nose</subject><subject>Observational studies</subject><subject>Otolaryngology</subject><subject>Patients</subject><subject>Quality of life</subject><subject>Questionnaires</subject><subject>Systematic review</subject><issn>0022-2151</issn><issn>1748-5460</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp1kUtv1DAUhS0EotPCD2CDLLFh0YAdO_GYHRrxkip1QVlHftxMXCVx8AOUX8LfxdMZQGrF3XhxvnPutQ5CLyh5QwkVb78SUtc1bSiVpIzkj9CGCr6tGt6Sx2hzkKuDfobOY7wtCBWkforOGGkFZ43YoF83A2AzqHkPEbsZW9f3EGBOOK7TkvyEo_GhaDYHN-9xzNrkpGbwufDTlGefBghqWQ_u3eBmiICHokKxxIQnlwCrcYSwdwYvKrkSHt9hhdNPX62gwiX2OkL4USQ_qxHHlO36DD3p1Rjh-em9QN8-frjZfa6urj992b2_qgwTLFUaVM-NZT1tidQtMfVW9VBvjWis1ErUXFBptj0TkjCtDAdLBJFgG04a3bTsAr0-5i7Bf88QUze5aGAcj1_saiokp5Ldoa_uobc-h3JxoWoiG0YZZ4WiR8oEH2OAvluCm1RYO0q6Q2vdg9aK5-UpOesJ7F_Hn5oKwE6hatLB2T382_3_2N8Mw6Qp</recordid><startdate>20190301</startdate><enddate>20190301</enddate><creator>Tu, Y</creator><creator>Zhang, H</creator><creator>Zhao, L</creator><creator>Jin, P</creator><creator>Zi, X</creator><creator>Li, T</creator><creator>Shi, L</creator><creator>Zhi, L</creator><general>Cambridge University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AF</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>S0X</scope><scope>7X8</scope></search><sort><creationdate>20190301</creationdate><title>The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study</title><author>Tu, Y ; Zhang, H ; Zhao, L ; Jin, P ; Zi, X ; Li, T ; Shi, L ; Zhi, L</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c373t-beaf4cd3f1609b60c28afe28c75d9ba724719c8f37903bac4ed0709ed5405b563</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Allergic rhinitis</topic><topic>Allergies</topic><topic>Asthma</topic><topic>Clinical trials</topic><topic>Histamine</topic><topic>Hospitals</topic><topic>Immunotherapy</topic><topic>Main Articles</topic><topic>Nose</topic><topic>Observational studies</topic><topic>Otolaryngology</topic><topic>Patients</topic><topic>Quality of life</topic><topic>Questionnaires</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tu, Y</creatorcontrib><creatorcontrib>Zhang, H</creatorcontrib><creatorcontrib>Zhao, L</creatorcontrib><creatorcontrib>Jin, P</creatorcontrib><creatorcontrib>Zi, X</creatorcontrib><creatorcontrib>Li, T</creatorcontrib><creatorcontrib>Shi, L</creatorcontrib><creatorcontrib>Zhi, L</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>STEM Database</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>SIRS Editorial</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of laryngology and otology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tu, Y</au><au>Zhang, H</au><au>Zhao, L</au><au>Jin, P</au><au>Zi, X</au><au>Li, T</au><au>Shi, L</au><au>Zhi, L</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study</atitle><jtitle>Journal of laryngology and otology</jtitle><addtitle>J. Laryngol. Otol</addtitle><date>2019-03-01</date><risdate>2019</risdate><volume>133</volume><issue>3</issue><spage>213</spage><epage>219</epage><pages>213-219</pages><issn>0022-2151</issn><eissn>1748-5460</eissn><abstract>Subcutaneous immunotherapy is an effective and safe treatment for allergic rhinitis and allergic asthma. Different symptom scores are used to evaluate the efficacy of subcutaneous immunotherapy in clinical trials.
A total of 58 allergic rhinitis patients sensitised to house dust mites, with or without mild asthma, were included. Symptom score, medication score, visual analogue scale score and quality of life were assessed before and after 6, 12 and 24 months of subcutaneous immunotherapy.
After two years of subcutaneous immunotherapy, asthma symptom scores nearly reached zero, whereas the scores remained higher for nasal symptoms. The changes in asthma symptom scores were markedly different (p < 0.05) and occurred faster than the changes in nasal symptom scores when compared between monosensitised and polysensitised groups. Significant reductions in visual analogue scale score and medication score were demonstrated after subcutaneous immunotherapy.
Two-year subcutaneous immunotherapy with house dust mite vaccine is an effective treatment for both monosensitised and polysensitised allergic patients. The changes in asthma symptom scores were markedly different and occurred quicker than the changes in nasal symptom scores in Chinese house dust mite allergic patients.</abstract><cop>Cambridge, UK</cop><pub>Cambridge University Press</pub><pmid>30674357</pmid><doi>10.1017/S0022215119000094</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-2151 |
| ispartof | Journal of laryngology and otology, 2019-03, Vol.133 (3), p.213-219 |
| issn | 0022-2151 1748-5460 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2179419356 |
| source | Cambridge University Press Journals Complete |
| subjects | Allergic rhinitis Allergies Asthma Clinical trials Histamine Hospitals Immunotherapy Main Articles Nose Observational studies Otolaryngology Patients Quality of life Questionnaires Systematic review |
| title | The changes in different symptom scores during subcutaneous immunotherapy in Chinese house dust mite allergic patients: a two-year, observational study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T05%3A07%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20changes%20in%20different%20symptom%20scores%20during%20subcutaneous%20immunotherapy%20in%20Chinese%20house%20dust%20mite%20allergic%20patients:%20a%20two-year,%20observational%20study&rft.jtitle=Journal%20of%20laryngology%20and%20otology&rft.au=Tu,%20Y&rft.date=2019-03-01&rft.volume=133&rft.issue=3&rft.spage=213&rft.epage=219&rft.pages=213-219&rft.issn=0022-2151&rft.eissn=1748-5460&rft_id=info:doi/10.1017/S0022215119000094&rft_dat=%3Cproquest_cross%3E2209531343%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2209531343&rft_id=info:pmid/30674357&rft_cupid=10_1017_S0022215119000094&rfr_iscdi=true |